Sanofi Healthcare India receives marketing authorization for Rezurock, a new treatment for chronic graft-versus-host disease ...

Sanofi Healthcare India has obtained marketing authorization for Rezurock, a drug for treating Chronic graft versus host ...

Sanofi Healthcare India receives marketing authorization for Rezurock (Belumosudil), a new treatment for Chronic Graft-versus-Host Disease (cGVHD) in adults and adolescents.

Saudi Arabia is now shifting toward localized production, a move that will significantly enhance national drug security and ...

The Indian subsidiary of French pharma major Sanofi has received marketing authorization for Rezurock (belumosudil tablets) in India.

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Sanofi Healthcare India has received marketing authorization for Rezurock, a drug for chronic graft versus host disease (cGVHD). Approved by USFDA and CDSCO, Rezurock offers a new treatment for ...

The latest health news covers topics such as the Trump administration's legal positions on transgender care, CDC research ...

Sanofi has agreed to purchase its own shares worth €2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...